Literature DB >> 22297735

Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines.

K Frenzel1, S Ganepola, D Michel, E Thiel, D H Krüger, L Uharek, J Hofmann.   

Abstract

Primary infection and reactivation of human cytomegalovirus (CMV) remain a major problem in immunocompromised patients, frequently resulting in a life threatening CMV disease. Intravenous polyvalent (hyper)-immunoglobulins (IVIG) can be administered for therapy and prophylaxis of CMV infections. However, only limited data about the efficacy and mechanism of action of IVIG products against viral infections in vitro are available so far. In this study, the effect of IVIG on CMV infection in vitro was investigated using isolates from CMV-infected patients as well as the laboratory strains AD169 and TB40. A qualitative and quantitative comparison of five different commercially available IVIG products in different human cell lines was performed concerning their ability (1) to neutralize cell-free virus, (2) to inhibit cell-to-cell spread and cell-associated transmission and (3) to influence CMV mRNA levels. All IVIG tested exhibited a high neutralization activity in epithelial and endothelial cell cultures (50% inhibition dose <0.1 mg/ml). However, qualitative differences between the products could be demonstrated in neutralization tests using human embryonal lung fibroblasts (HELF). The IVIG products also significantly differed in their ability to inhibit cell-to-cell spread within an CMV-infected HELF monolayer displaying inhibition rates that varied between 61 and 100%. No correlation between the ability to neutralize cell-free virus and to inhibit cell-to-cell spread could be observed. The incubation with IVIG influenced the amount of CMV immediate early and late mRNA, as indicated by a significant reduction in CMV mRNA in infected epithelial cells after incubation with IVIG in a dose-dependent manner. This study suggests different antiviral functions of polyvalent IVIG and confirms their potential to inhibit a CMV infection in vitro, with profound differences between the hereby used IVIG products.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22297735     DOI: 10.1007/s00430-012-0229-2

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  38 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Measurement and assessment of cytomegalovirus of immunoglobulin (Ig) g titer in preparations.

Authors:  Hirotomo Shibaguchi; Tomoka Yamamoto; Masahide Kuroki; Koujiro Futagami
Journal:  Yakugaku Zasshi       Date:  2010-07       Impact factor: 0.302

Review 3.  Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis.

Authors:  Pia Raanani; Anat Gafter-Gvili; Mical Paul; Isaac Ben-Bassat; Leonard Leibovici; Ofer Shpilberg
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

4.  Passive immunization during pregnancy for congenital cytomegalovirus infection.

Authors:  Giovanni Nigro; Stuart P Adler; Renato La Torre; Al M Best
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

5.  Circulating cytomegalovirus (CMV) neutralizing activity in bone marrow transplant recipients: comparison of passive immunity in a randomized study of four intravenous IgG products administered to CMV-seronegative patients.

Authors:  A H Filipovich; M H Peltier; M K Bechtel; C L Dirksen; S A Strauss; J A Englund
Journal:  Blood       Date:  1992-11-15       Impact factor: 22.113

Review 6.  Human cytomegalovirus DNA replication: antiviral targets and drugs.

Authors:  Beatrice Mercorelli; Elisa Sinigalia; Arianna Loregian; Giorgio Palù
Journal:  Rev Med Virol       Date:  2008 May-Jun       Impact factor: 6.989

7.  Antiviral activity against CMV-infected fibroblasts in pediatric patients transplanted with CD34(+)-selected allografts from alternative donors.

Authors:  P Lang; A Griesinger; K Hamprecht; T Feuchtinger; M Schumm; F Neuhäuser; J Greil; D Martin; R Handgretinger; D Niethammer
Journal:  Hum Immunol       Date:  2004-05       Impact factor: 2.850

8.  Cytomegalovirus evasion of innate immunity by subversion of the NKR-P1B:Clr-b missing-self axis.

Authors:  Sebastian Voigt; Aruz Mesci; Jakob Ettinger; Jason H Fine; Peter Chen; Wayne Chou; James R Carlyle
Journal:  Immunity       Date:  2007-04-26       Impact factor: 31.745

9.  Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H.

Authors:  L Li; K L Coelingh; W J Britt
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

10.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.

Authors:  Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113

View more
  9 in total

Review 1.  Vaccination against infectious diseases: what is promising?

Authors:  Hans Wilhelm Doerr; Annemarie Berger
Journal:  Med Microbiol Immunol       Date:  2014-07-27       Impact factor: 3.402

2.  Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection.

Authors:  K Frenzel; J Lehmann; D H Krüger; L Martin-Parras; L Uharek; J Hofmann
Journal:  Med Microbiol Immunol       Date:  2013-12-15       Impact factor: 3.402

3.  Natural killer cells can inhibit the transmission of human cytomegalovirus in cell culture by using mechanisms from innate and adaptive immune responses.

Authors:  Zeguang Wu; Christian Sinzger; Johanna Julia Reichel; Marlies Just; Thomas Mertens
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

4.  Efficacy and safety of intravenous high-dose immunoglobulin in treatment of the severe form of Japanese encephalitis.

Authors:  Dan Chen; Xiaoling Peng; Yu Zhan; Peng Wu; Li Jiang; Yue Hu
Journal:  Neurol Sci       Date:  2022-01-19       Impact factor: 3.307

5.  The pentameric complex drives immunologically covert cell-cell transmission of wild-type human cytomegalovirus.

Authors:  Isa Murrell; Carmen Bedford; Kristin Ladell; Kelly L Miners; David A Price; Peter Tomasec; Gavin W G Wilkinson; Richard J Stanton
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-22       Impact factor: 12.779

6.  Neutralizing Antibodies Limit Cell-Associated Spread of Human Cytomegalovirus in Epithelial Cells and Fibroblasts.

Authors:  Nina Reuter; Barbara Kropff; William J Britt; Michael Mach; Marco Thomas
Journal:  Viruses       Date:  2022-01-28       Impact factor: 5.048

7.  The viral chemokine MCK-2 of murine cytomegalovirus promotes infection as part of a gH/gL/MCK-2 complex.

Authors:  Felicia M Wagner; Ilija Brizic; Adrian Prager; Tihana Trsan; Maja Arapovic; Niels A W Lemmermann; Jürgen Podlech; Matthias J Reddehase; Frederic Lemnitzer; Jens Bernhard Bosse; Martina Gimpfl; Lisa Marcinowski; Margaret MacDonald; Heiko Adler; Ulrich H Koszinowski; Barbara Adler
Journal:  PLoS Pathog       Date:  2013-07-25       Impact factor: 6.823

8.  Establishment of HSV1 latency in immunodeficient mice facilitates efficient in vivo reactivation.

Authors:  Chandran Ramakrishna; Adrianna Ferraioli; Aleth Calle; Thanh K Nguyen; Harry Openshaw; Patric S Lundberg; Patrick Lomonte; Edouard M Cantin
Journal:  PLoS Pathog       Date:  2015-03-11       Impact factor: 6.823

9.  Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas.

Authors:  Takako Tabata; Matthew Petitt; June Fang-Hoover; Daniel C Freed; Fengsheng Li; Zhiqiang An; Dai Wang; Tong-Ming Fu; Lenore Pereira
Journal:  Vaccines (Basel)       Date:  2019-09-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.